Chimeric Therapeutics Limited (CHMMF)

OTCMKTS · Delayed Price · Currency is USD
0.0010
-0.0290 (-96.67%)
At close: Sep 6, 2024
-96.67%
Market Cap4.26M
Revenue (ttm)8.32M
Net Income (ttm)-6.84M
Shares Outn/a
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,000
Average Volume20,438
Open0.0010
Previous Close0.0300
Day's Range0.0010 - 0.0010
52-Week Range0.0010 - 0.0350
Beta1.54
RSIn/a
Earnings DateAug 29, 2025

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 express... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country Australia
Stock Exchange OTCMKTS
Ticker Symbol CHMMF
Full Company Profile

Financial Performance

In 2025, Chimeric Therapeutics's revenue was 12.68 million, an increase of 70.09% compared to the previous year's 7.46 million. Losses were -10.43 million, -16.76% less than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.